[Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading ->
Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading ->
The World Health Organization’s new guidelines on digital health highlight the value of digital health technologies in helping to close health system gaps, while emphasising that they do not replace investments in health system infrastructure. The guidelines assess the appropriateness of a range of digital health technologies and provide recommendations on making informed investments in […] Continue reading ->
[Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and […] Continue reading ->